| 1 |
Phase 1 development of Axl, Mer, CSF1R inhibitor Q702 |
| Small molecules |
cGVHD |
Axl, Mer, CSF1R |
Phase 1 |
Qurient Co., Ltd. |
RS-2025-02213024 |
|
| 2 |
IM.101: Complement Inhibitor for Autoimmune Diseases |
| Antibody |
Autoimmune diseases |
Human Complement C5 |
Phase 1 |
ImmunAbs |
RS-2023-00258444 |
|
| 3 |
Development of a therapeutic agent for ulcerative colitis by regulating glycogen metabolism of
immune cells and intestinal epithelial cells |
| Small molecules |
Ulcerative Colitis |
PYGL |
Phase 1 |
INNOVO Therapeutics |
RS-2022-00166802 |
|
| 4 |
Topical immunotherapeutic agent for atopic dermatitis : FPR2-selective pro-resolving peptide ligand |
| rProtein |
Atopic dermatitis |
FPR2 |
Phase 1 |
Novacell technology Inc. |
HN21C1061 |
|